Federal Women’s Health Division to Prioritize Endometriosis, Fibroids, and Menopause; Patient Benefits May Take Years

On Oct. 19, President Donald Trump signed an executive order directing the Department of Health and Human Services (HHS) to establish a Women’s Health Division within the National Institutes of Health (NIH) within 90 days. The order identifies a broad set of conditions that disproportionately affect women—including endometriosis, fibroids, menopause, infertility, and a range of other diseases—as research priorities, though it does not allocate funding or specify staffing details.

Conditions on the New Research Agenda

The order enumerates conditions it says uniquely or disproportionately impact women: heart disease, cancer, stroke, Alzheimer’s disease, autoimmune and inflammatory disorders, osteoporosis, mental health conditions, chronic pain, endometriosis, fibroids, infertility, maternal health, menopause, neurological disorders, aging, and “polyendocrine metabolic ovarian syndrome” (PMOS), the newly adopted name for polycystic ovary syndrome. The division is expected to review understudied areas, coordinate research efforts, accelerate diagnostic technologies, increase participation of women and girls in clinical trials, and ensure NIH grantees consider sex as a biological variable.

Research Timelines and Unanswered Questions

Advancing care through research typically requires years: study design, funding, execution, peer review, publication, guideline adoption, and, for new therapies, FDA approval. The order calls for technologies that could speed diagnosis—such as a reliable blood test or imaging method for endometriosis—but does not guarantee immediate outcomes.

Key details remain unclear. The order does not specify budget, staff size, or which NIH institute will house the division. It also revokes President Joe Biden’s March 2024 executive order and a 2023 presidential memorandum on women’s health research. Recent HHS actions, including a brief halt to contracts for the Women’s Health Initiative, have added to uncertainty.

Practical Steps for Patients Now

While the new division is being organized, existing treatment options remain accessible. Women experiencing pelvic pain, heavy periods, irregular cycles, or disruptive menopause symptoms should continue seeking care. Keeping a symptom diary—tracking pain, bleeding, sleep, and mood—can aid clinicians in diagnosing conditions like endometriosis. If a patient feels dismissed, requesting a referral to a gynecologist or menopause specialist is advisable.

Individuals interested in shaping future research can explore ClinicalTrials.gov or ask their physicians about nearby academic studies. Participation is voluntary, and patients should inquire about costs, travel support, and study withdrawal policies. Insurance coverage for specialists, imaging, and hormone therapy varies; patients facing denials can seek guidance on prior authorization and appeals, and should not discontinue prescribed therapies without consulting their clinicians.

The 90‑day deadline for establishing the NIH division falls in mid‑January 2027.

Key Questions Answered

What does the executive order do? It mandates HHS to create a Women’s Health Division at NIH within 90 days and establishes a White House Women’s Health Task Force co‑chaired by HHS Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles.

Which conditions are named? The order lists endometriosis, fibroids, menopause, infertility, PMOS, maternal health, heart disease, cancer, osteoporosis, Alzheimer’s disease, and others.

Is there new funding? No specific funding is set; implementation depends on congressional appropriations.

Will this change my treatment soon? Unlikely. Research typically takes years to influence clinical practice, and the division has not yet been formed.

What happened to the earlier women’s health order? The new order revokes President Biden’s March 2024 executive order and a 2023 presidential memorandum on women’s health research.

What can patients do now? Track symptoms, seek specialist referrals when needed, ask about clinical trials, and continue any prescribed treatments while navigating insurance and prior‑authorization processes.

Source link